Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Friday, April 15, 2016

14 MS Experimental Therapies You Should Know About

APRIL 13, 2016 -  BY ANDREIA PEIXOTO 


news_11_Artboard 343 copy 92

1. ALKS 8700

Alkremes Inc. is developing a novel formulation called ALKS 8700 to treat demyelinating neurodegenerative disorders of the central nervous system such as multiple sclerosis (MS).

2. AP-1

Ankar Pharmaceuticals, a Spanish-Filipino start-up in biopharmaceuticals, has been working on the development of their premier drug candidate for treating multiple sclerosis (MS), called AP-1. The unique property of this pipeline drug is its ability to excel in terms of prophylactic measures in people suspected to be affected by the condition, as well as in those with a full-blown case history of MS and relapses. This gives the oral formulation an advantageous edge over many contemporary drugs, fingolimod being the latest to be approved, for treating MS.

3. APD334

APD334 is Arena Pharmaceuticals’ latest novel therapeutic remedy to treat autoimmune diseases like multiple sclerosis (MS), psoriasis and rheumatoid arthritis. The drug is an oral formulation, which is also an agonist (a substance which exerts its effect after binding to a particular receptor) of the S1P1 receptor. This receptor is involved in the regulation of immune responses in the body and hence is a potent target to treat autoimmune disorders.

4. ATL1102

Antisense Therapeutics is currently developing ATL1102, a novel therapeutic candidate for treating relapsing and remitting forms of multiple sclerosis (MS). ATL1102 is an antisense inhibitor of the CD49d subunit of the VLA-4 (Very Late Antigen-4) receptor on the surface of lymphocytes. The concept of making antisense drugs (therapies containing the non-coding part of a messenger RNA molecule, which is a key component of DNA replication and protein synthesis, to end the process of protein synthesis of that particular gene which is the causative agent of a particular condition) has been used over the years to treat different types of cancers, amyotropic lateral sclerosis, diabetes and diseases like asthma and arthritis, with an inflammatory component.

5. BN201

California-based pharmaceutical company Bionure is currently developing a novel neuroprotective and remyelinating therapy called BN201 for acute optic neuritis (AON), glaucoma (GL) and multiple sclerosis (MS).

6.CTP-354

CTP-354 is Concert Pharmaceuticals’ novel, potentially first-in-class, non-sedating, once-daily oral formulation aimed at treating conditions like cerebral palsy, multiple sclerosis (MS), amyotropic lateral sclerosis (ALS), spinal cord injury and hereditary paraplegia, all of which contribute to spasticity in humans. As part of developing CTP-354, Concert is utilizing the deuterated chemical entity DCE platform, which involves the addition and modification of existing, approved drugs or those studied clinically beforehand with deuterium to improve safety and clinical efficacy.
                                            ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News 
Providing educational information and resources for those affected by MS
Keep current with Multiple Sclerosis news and information 
To opt-in (sign-up) at our website: click here - thank you
.===================================

No comments: